Teri Deffenbaugh, DO
Obstetrics & Gynecology · Jefferson City, MONPI 1427006071
Payments from drug & device makers
Across 162 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$471
- Pfizer$329
- Coopersurgical, Inc.$303
- Johnson & Johnson$194
- Astellas Pharma US Inc$185
- Exeltis, USA Inc.$149
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,909100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $471 |
| Pfizer | 21 | $329 |
| Coopersurgical, Inc. | 5 | $303 |
| Johnson & Johnson | 9 | $194 |
| Astellas Pharma US Inc | 9 | $185 |
| Exeltis, USA Inc. | 9 | $149 |
| Organon | 10 | $146 |
| Therapeuticsmd, Inc. | 9 | $129 |
| Daiichi Sankyo Inc. | 6 | $111 |
| Bayer | 7 | $96 |
| Hologic Sales And Service, LLC | 5 | $91 |
| Covidien LP | 3 | $73 |
| Novo Nordisk | 5 | $72 |
| Davol Inc. | 3 | $64 |
| Amgen | 4 | $56 |
| Merck | 4 | $52 |
| Exact Sciences | 3 | $51 |
| Mayne Pharma Commercial LLC | 3 | $47 |
| Myovant Sciences Inc. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Minerva Surgical, Inc | 2 | $32 |
| Monaghan Medical Corporation | 1 | $26 |
| Dysis Medical, Inc. | 2 | $23 |
| Meditrina | 1 | $22 |
| Smith+Nephew | 1 | $21 |
| Roche Diagnostics Corporation | 1 | $19 |
| Hydrofera LLC | 1 | $19 |
| Millicent US Inc | 1 | $16 |
| Medtronic | 1 | $15 |
| Boston Scientific | 1 | $12 |
| Lupin Inc. | 1 | $11 |
| Intuitive Surgical | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Paragard$125
How this compares
$2,916 in reported general payments places this provider in the 80th percentile of 750 obstetrics & gynecology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 33 | $30,315 |
| OsphenaOspemifene | 34 | $16,672 |
| Estradiol | 179 | $15,838 |
| GemtesaVibegron | 25 | $13,929 |
| ProgesteroneProgesterone, Micronized | 121 | $7,776 |
| IntrarosaPrasterone (Dhea) | 16 | $6,653 |
| PremarinEstrogens, Conjugated | 13 | $5,729 |
| ImvexxyEstradiol | 16 | $4,139 |
| Estradiol (Twice Weekly)Estradiol | 38 | $3,685 |
| YuvafemEstradiol | 30 | $3,628 |
| Solifenacin Succinate | 47 | $2,597 |
| DottiEstradiol | 23 | $2,106 |
| Clobetasol Propionate | 50 | $1,021 |
| ValacyclovirValacyclovir Hcl | 14 | $592 |
| Raloxifene Hcl | 12 | $489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $185 | $30,31533 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $35 | $13,92925 claims |
| PfizerPremarin | $329 | $5,72913 claims |
| Therapeuticsmd, Inc.Imvexxy | $129 | $4,13916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 750 obstetrics & gynecology providers in Missouri.
Other obstetrics & gynecology in Jefferson City
- Brandi NicholsJefferson City$8K
- Thomas ShultzSpringfield$1.1M
- Kent BransonCreve Coeur$576K
- Saji JacobSt. Louis$411K
- Becky LynnSaint Louis$231K
- Timothy HallIndependence$172K
- Craig McCoyMoberly$101K
- Andrew DavisSt. Louis$75K
- Richard GutknechtIndependence$65K
- Amanda CarrollFestus$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.